Aspirin and Clopidogrel for Prevention of Ischemic Stroke

Papers of particular interest, published recently, have been highlighted as: • Of importance, •• Of major importance

1. 1.
   Fisher CM. Observations of the fundus oculi in transient monocular blindness. Neurology. 1959;9:333–47.PubMedCrossRefGoogle Scholar
2. 2.
   Carter A. Use of anticoagulants in patients with progressive cerebral infarction. Neurology. 1961;11:601–9.PubMedCrossRefGoogle Scholar
3. 3.
   Baker RN, Broward HC, Fang HC. Anticoagulant therapy in cerebral infarction: Report on cooperative study. Neurology. 1962;12:823–35.Google Scholar
4. 4.
   Craven LL. Acetylsalicylic acid: possible preventive of coronary thrombosis. Ann West Med Surg. 1950;4:95–9.PubMedGoogle Scholar
5. 5.
   Weiss HJ, Aledort LM. Impaired platelet connective-tissue reaction in man after aspirin ingestion. Lancet. 1967;2:495–7.PubMedCrossRefGoogle Scholar
6. 6.
   Jorgensen L, Rowsell HC, Hovig T, Glynn MF, Mustard JF. Adenosine diphosphate-induced platelet aggregation and myocardial infarction in swine. Laboratory Investigation. 1967;17:616–44.PubMedGoogle Scholar
7. 7.
   Harrison MJG, Marshall J, Meadows JC, Russell RWR. Effect of aspirin in amaurosis fugax. Lancet. 1971;2:734–44.Google Scholar
8. 8.
   Coller BS. Historical perspectives and future directions in platelet research. J Thromb Haemost. 2011;9 Suppl 1:374–95.PubMedCrossRefGoogle Scholar
9. 9.
   FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJD, Lawson JA, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983;71:676–88.PubMedCrossRefGoogle Scholar
10. 10.
    Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334:1084–9.PubMedCrossRefGoogle Scholar
11. 11.
    Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. Stroke. 1977;8:301–16.PubMedCrossRefGoogle Scholar
12. 12.
    The Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med.1978;13;299(2):53–9.Google Scholar
13. 13.
    Bousser MG, Eschwege E, Haguenau M, Lefaucconnier JM, Thibult N, Touboul D, et al. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke. 1983;14(1):5–14.PubMedCrossRefGoogle Scholar
14. 14.
    The ESPS. Group. The European Stroke Prevention Study (ESPS). Principal end-points. Lancet. 1987;2(8572):1351–4.Google Scholar
15. 15.
    Anderson DC. Progress report of the Stroke Prevention in Atrial Fibrillation Study. Stroke. 1990;21(Suppl 11): III12–7.Google Scholar
16. 16.
    Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54(12):1044–54.PubMedCrossRefGoogle Scholar
17. 17.
    The Dutch TIA Trial Study Group. A comparison of 2 doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. N Engl J Med. 1991;325(18):1261–6.Google Scholar
18. 18.
    Collins R, Baigent C, Sandercock P, Peto R. Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomized trials. Antiplatelet Trialists' Collaboration. BMJ. 1994;309(6963):1215–7.PubMedCrossRefGoogle Scholar
19. 19.
    Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143(1–2):1–13.PubMedCrossRefGoogle Scholar
20. 20.
    CAST Collaborative Group. CAST (Chinese Acute Stroke Trial). Randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet. 1997;349(9066):1649.Google Scholar
21. 21.
    International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke. Lancet. 1997;349(9065):1569–81.CrossRefGoogle Scholar
22. 22.
    The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants vs aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol. 1997;42(6):857–65.CrossRefGoogle Scholar
23. 23.
    Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin vs aspirin in patients with acute ischemic stroke and atrial fibrillation: a double-blind randomized study. Lancet. 2000;355(9211):1205–10.PubMedCrossRefGoogle Scholar
24. 24.
    Hankey GJ. Warfarin-Aspirin Recurrent Stroke Study (WARSS) Trial: is Warfarin really a reasonable therapeutic alternative to Aspirin for preventing recurrent noncardioembolic ischemic stroke? Stroke. 2002;33:1723–6.PubMedCrossRefGoogle Scholar
25. 25.
    Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71.Google Scholar
26. 26.
    Sauvageau E, Ecker RD, Levy EI, Hanel RA, Guterman LR, Hopkins LN. Recent advances in endoluminal revascularization for intracranial atherosclerotic disease. Neurol Res. 2005;27(Suppl 1):S89–94. (WASID)Google Scholar
27. 27.
    Sandercock PA, Counsell C, Gubitz GJ, Tseng MC. Antiplatelet therapy for acute ischemic stroke. Cochrane Database Syst Rev. 2008;3:CD000029.Google Scholar
28. 28.
    IST 1991Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet. 2009;373:1849–60.Google Scholar
29. 29.
    •• Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, et al. WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012;366(20):1859–69. This study found patients with reduced LVEF but sinus rhythm have a reduced risk of ischemic stroke when treated with warfarin, however this benefit is offset by the increased risk of hemorrhage. This prompts the need for individualization of the choice between aspirin or warfarin.Google Scholar
30. 30.
    Moher JP, et al. N Engl J Med. 2001;345:144–1451.CrossRefGoogle Scholar
31. 31.
    Dale J, Myhre E, Storstein O, Stormorken H, Efskind L. Prevention of arterial thromboembolism with acetylsalicylic acid: a controlled clinical study in patients with aortic ball valves. Am Heart J. 1977;95(1):101–11.CrossRefGoogle Scholar
32. 32.
    • Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunsø J, Gadsbøll N, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170:1433–41. This study found warfarin combined with aspirin and/or clopidogrel has a 3‐fold higher risk when compared to warfarin monotherapy.Google Scholar
33. 33.
    Kronmal RA, Hart RG, Manolio TA, Talbert RL, Beauchamp NJ, Newman A. Aspirin use and incident stroke in the Cardiovascular Health Study. Stroke. 1988;29:887–94.CrossRefGoogle Scholar
34. 34.
    Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med. .1989;321:129–35.Google Scholar
35. 35.
    •• Raju NC, Eikelboom JW. The aspirin controversy in primary prevention. Current Opin Cardiol. 2012;27(5):499–507. This study found the risks of primary prevention with aspirin for individuals at low risk for cardiovascular disease may outweigh the benefits as aspirin reduces the risk of MI, but at the cost of an increase in major bleeding with a nominally significant reduction in total mortality.Google Scholar
36. 36.
    • Hassan C, Rex DK, Cooper GS, Zullo A, Launois R, Benamouzig R. Primary prevention of colorectal cancer with low-dose aspirin in combination with endoscopy: a cost-effectiveness analysis. Gut. 2012;61 (8):1172–9. This study is significant because it demonstrated the addition of low dose aspirin is efficacious in preventing proximal colorectal cancer, indicating that the use of aspirin may have benefits beyond that of primary prevention of cardiovascular disease. Google Scholar
37. 37.
    Siller-Matula JM. Hemorrhagic complications associated with aspirin: an underestimated hazard in clinical practice? JAMA. 2012;307(21):2318–20.PubMedCrossRefGoogle Scholar
38. 38.
    McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med. 2006;119(8):624–38.PubMedCrossRefGoogle Scholar
39. 39.
    Tamura T, Sakaeda T, Kadoyama K, Okuno Y. Aspirin- and Clopidogrel-associated bleeding complications: data mining of the public version of the FDA Adverse Event Reporting System, AERS. Int J Med Sci. 2012;9(6):441–6.PubMedCrossRefGoogle Scholar
40. 40.
    Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989;1(8649):1215–20.PubMedCrossRefGoogle Scholar
41. 41.
    Goyan JE. The "trials" of a long-term clinical trial: the Ticlopidine Aspirin Stroke Study and the Canadian-American Ticlopidine Study. Control Clin Trials. 1989;10 Suppl 4:236S–44S.PubMedCrossRefGoogle Scholar
42. 42.
    CAPRIE steering Committee. A randomized, blinded, trial of clopidogrel vs aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348:1329–39.Google Scholar
43. 43.
    Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. (MATCH investigators). Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):331–7.PubMedCrossRefGoogle Scholar
44. 44.
    Bhatt DL, Fox KA, Hacke W, for the CHARISMA Investigators, et al. Clopidogrel and aspirin vs aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–17.PubMedCrossRefGoogle Scholar
45. 45.
    Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM, FASTER Investigators. Fast assessment of stroke and transient ischemic attack to prevent early recurrence (FASTER): a randomized controlled pilot trial. Lancet Neurol. 2007;6:961–9.PubMedCrossRefGoogle Scholar
46. 46.
    Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al. Aspirin and extended-release dipyridamole vs clopidogrel for recurrent stroke. N Engl J Med. 2008;359(12):1238–51.PubMedCrossRefGoogle Scholar
47. 47.
    The ACTIVE Investigators. Effect of Clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360:2066–207.CrossRefGoogle Scholar
48. 48.
    The SPS3 Investigators. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012;367:817–25.Google Scholar
49. 49.
    Chan F. Antiplatelet therapy and managing ulcer risk. J Gastroenterol Hepatol. 2012;27(2):195–9.PubMedCrossRefGoogle Scholar
50. 50.
    Qureshi AL, Luft AR, Sharma M, Guterman LR, Hopkins LN. Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures: Part I–pathophysiological and pharmacological features. Neurosurgery. 2000;46(6):1344–59.PubMedCrossRefGoogle Scholar
51. 51.
    Halkes PH, van Gijn J, Kappelle LJ, Koudstssl PJ, Algra A, ESPRIT Study Group. Aspirin plus dipyridamole vs aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomized controlled trial. Lancet. 2006;367:1665–73.PubMedCrossRefGoogle Scholar
52. 52.
    CURE Study investigators. The clopidogrel in unstable angina to prevent recurrent events (CURE) trial program: rational, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J. 2000;21:2033–41.CrossRefGoogle Scholar
53. 53.
    Oldag A, Schreiber S, Schreiber S, Heinze HJ, Meyer F, Weber M, et al. Risk of wound hematoma at carotid endarterectomy under dual antiplatelet therapy. Langenbecks Arch Surg. 2012 [Epub ahead of print].Google Scholar
54. 54.
    POINT TRIAL Available at: http://www.pointtrial.org/. Accessed 1 Oct 2012.
55. 55.
    Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the clopidogrel and aspirin for reduction of emboli in symptomatic carotid stenosis (CARESS) trial. Circulation. 2005;111(17):22333–40.CrossRefGoogle Scholar
56. 56.
    Wong KS, Chen C, Fu J, Chang HM, Suwanwela NC, Huang YN, et al. CLAIR study investigators. Lancet Neurol. 2010;9(5):489–97.Google Scholar
57. 57.
    •• Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, et al. SAMMPRIS Trial Investigators. Stenting vs aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011;365(11):993–1003. This study found aggressive medical management including dual antiplatelet therapy was superior to percutaneous transluminal angioplasty and stenting (PTAS) with use of the Wingspan stent system due to the increased risk of early stroke aNer PTAS. Google Scholar
58. 58.
    Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360(20):2066–78.PubMedCrossRefGoogle Scholar
59. 59.
    Yamane K, Ikeda T, Taniguchi R, Watanabe S, Kawato M, Kondo H, et al. Impact of platelet reactivity on long‐term clinical outcomes and bleeding events in Japanese patients receiving antiplatelet therapy with aspirin. J Atheroscler Thromb. 2012;19(12):1142–53.Google Scholar
60. 60.
    Siller-Matula JM, Delle-Karth G, Christ G, Neunteufl T, Maurer G, Huber K, et al. Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. Int J Cardiol. 2012.Google Scholar
61. 61.
    Depta JP, Fowler J, Novak E, Katzan I, Bakdash S, Kottke-Marchant K, et al. Clinical outcomes using a platelet function-guided approach for secondary prevention in patients with ischemic stroke or transient ischemic attack. Stroke. 2012.Google Scholar
62. 62.
    Frelinger AL, Li Y, Linden MD, Tarnow I, Barnard MR, Fox ML, et al. Aspirin “resistance” role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost. 2008;6:2035–44.PubMedCrossRefGoogle Scholar
63. 63.
    Fong J, Cheng-Ching E, Hussain MS, Katzan I, Gupta R. Predictors of biochemical aspirin and clopidogrel resistance in patients with ischemic stroke. J Stroke Cerebrovasc Dis. 2011;20(3):227–30.PubMedCrossRefGoogle Scholar
64. 64.
    Htun P, Fateh-Moghadam S, Bischofs C, Banya W, Müller K, Bigalke B, et al. Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention. J Am Soc Nephrol. 2011;22(4):627–33.PubMedCrossRefGoogle Scholar
65. 65.
    Cuisset T, Frere C, Quilici J, Morange PE, Mouret JP, Bali L, et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. JACC Cardiovasc Interv. 2008;1:649–53.PubMedCrossRefGoogle Scholar
66. 66.
    Bonello L, Camoin-Jau L, Armero S, Com O, Arques S, Burignat-Bonello C, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol. 2009;103:5–10.PubMedCrossRefGoogle Scholar
67. 67.
    Aradi D, Komócsi A, Price MJ, Cuisset T, Ari H, Hazarbasanov D, et al. on behalf of the Tailored Antiplatelet Treatment Study Collaboration. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis. Int J Cardiol. 2012.Google Scholar
68. 68.
    Bigalke B, Schuster A, Sopova K, Wurster T, Stellos K. Platelets in atherothrombosis - diagnostic and prognostic value of platelet activation in patients with atherosclerotic diseases. Curr Vasc Pharmacol. 2012;[Epub ahead of print].Google Scholar
69. 69.
    Frocks J, Brouwer MA, van Oijen MG, Lanas A, Bhatt DL, Verheugt FW. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review. Heart. 2012 [Epub ahead of print].Google Scholar
70. 70.
    Capone ML, Sciulli MG, Tacconelli S, Grana M, Ricciotti E, Renda G, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol. 2005;45:1295–301.PubMedCrossRefGoogle Scholar
71. 71.
    Chen ZM, Jiang LX, Chen YP. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet. 2005;366:1607–21.PubMedCrossRefGoogle Scholar
72. 72.
    Shuldiner AR, O’Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849–57.PubMedCrossRefGoogle Scholar
73. 73.
    Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304:1821–30.PubMedCrossRefGoogle Scholar
74. 74.
    US Food and Drug Administration. "FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug". Drug Safety and Availability. Food and Drug Administration (United States). March 12, 2010.Google Scholar
75. 75.
    Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CyP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA. 2011;306(24):2709–14.CrossRefGoogle Scholar
76. 76.
    Sharma V, Kaul S, Al-Hazzani A, Alshatwi AA, Jyothy A, Munshi A. Association of COX-2 rs20417 with aspirin resistance. J Thromb Thrombolysis. 2012.Google Scholar
77. 77.
    Breet NJ, Sluman MA, van Berkel MA, van Werkum JW, Bouman HJ, Harmsze AM, et al. Effect of gender difference on platelet reactivity. Neth Heart J. 2011;19(11):451–7.PubMedCrossRefGoogle Scholar
78. 78.
    Cay S, Cagirci G, Aydogdu S, Balbay Y, Sen N, Maden O, et al. Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, 2-center study. Drugs Aging. 2011;28(2):119–29.PubMedCrossRefGoogle Scholar
79. 79.
    Kozinski M, Bielis L, Wisniewska-Szmyt J, Boinska J, Stolarek W, Marciniak A, et al. Diurnal variation in platelet inhibition by clopidogrel. Platelets. 2011;22(8):579–87. doi: 10.3109/09537104.2011.582900 [Epub 2011 May 31].PubMedCrossRefGoogle Scholar
80. 80.
    Palacio S, Hart RG, Pearce LA, Anderson DC, Sharma M, Birnbaum LA, et al. Effect of addition of clopidogrel to aspirin on stroke incidence: meta-analysis of randomized trials. Pending publication.Google Scholar